Abstract:Abstract Background Increasing cases of pulmonary aspergillosis (IPA) in immunocompetent patients with severe influenza have been reported. Howevere, the risk factors for occurence and death are largely unknown. Methods Data of hospitalised patients with influenza A-related pneumonia (FluA-p) obtained from five teaching hospitals from 2031 to 2018, were reviewed. Univariate and multivariate logistical regression analyses were performed to determine the risk factors involved in the acquisition and 60-day mortality in IPA patients. Results Of the 693 FluA-p patients included in the study, 3.0% (21/693) were IPA patients with a 60-day mortality of 42.9% (9/21). Adjusted for confounders, a Cox proportional hazard model showed that IPA was associated with increased risk for 60-day mortality [hazard ratio ( HR) 4.336, 95% confidence interval (CI) 1.191–15.784, p = 0.026] in FluA-p patients. A multivariate logistic regression model confirmed that age (odd ratio ( OR) 1.147, 95% CI 1.048–1.225, p = 0.003), systemic corticosteroids use before IPA diagnosis ( OR 33.773, 95% CI 5.681–76.764, p 10 × 10 9 /L ( OR 1.988, 95% CI 1.028–6.454, p = 0.029) and lymphocytes < 0.8 × 10 9 /L on admission ( OR 34.813, 95% CI 1.676–73.006, p = 0.022), were related with the acquisition of IPA. Early neuraminidase inhibitor use ( OR 0.290, 95% CI 0.002–0.584, p = 0.021) was associated with a decreased risk for a 60-day mortality in IPA patients. Conclusions Our results showed that IPA worsen the clinical outcomes of FluA-p patients. The risk factors for the acquisition and death were helpful for the clinicians in preventing and treating IPA.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the incidence and risk factors of invasive pulmonary aspergillosis (IPA) in immunocompetent adult patients during hospitalization for influenza A - related pneumonia, and to investigate the impact of IPA on the mortality of these patients within 60 days. Specifically, the study aims to: 1. **Investigate the incidence and risk factors of IPA during hospitalization for influenza A - related pneumonia in immunocompetent adult patients**: Through retrospective analysis of data from five teaching hospitals, the study determined which factors were associated with the occurrence of IPA. 2. **Explore the risk factors for death within 60 days in IPA patients**: Through statistical analysis, the researchers attempted to identify which factors would affect the survival rate of IPA patients. ### Main findings 1. **Incidence and impact of IPA**: - Among 693 immunocompetent patients hospitalized for influenza A - related pneumonia, 3.0% (21/693) of the patients developed IPA. - The 60 - day mortality rate of IPA patients was 42.9% (9/21), which was significantly higher than that of the control group (18.9%, 127/672). - After adjusting for confounding factors, the Cox proportional - hazards model showed that IPA increased the 60 - day death risk of patients with influenza A - related pneumonia by approximately 4.34 times (HR = 4.336, 95% CI 1.191 – 15.784, p = 0.026). 2. **Risk factors for IPA**: - Age (for each additional year of age, the risk increased by 1.147 times, 95% CI 1.048 – 1.225, p = 0.003). - Use of systemic corticosteroids before diagnosis (OR = 33.773, 95% CI 5.681 – 76.764, p < 0.001). - White blood cell count > 10 × 10^9/L (OR = 1.988, 95% CI 1.028 – 6.454, p = 0.029). - Lymphocyte count < 0.8 × 10^9/L at admission (OR = 34.813, 95% CI 1.676 – 73.006, p = 0.022). 3. **Predictors of 60 - day mortality**: - Early use of neuraminidase inhibitors (NAIs) was associated with a reduced 60 - day mortality (OR = 0.290, 95% CI 0.002 – 0.584, p = 0.021). ### Conclusion The study results indicate that IPA can significantly worsen the clinical outcomes of patients with influenza A - related pneumonia. Identifying high - risk factors is of great significance for the prevention and treatment of IPA. Early use of neuraminidase inhibitors may help improve the prognosis of IPA patients.

Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study